Costing the United States an estimated $20bn every year, the fight against so-called ‘superbugs’ is set to spiral into a global pandemic, causing up to 10 million deaths by 2050.
Edison Group’s client OpGen, Inc. has developed rapid testing solutions designed to stave off this bleak future. And in the last quarter it has made considerable progress in expanding its portfolio offerings and market reach. As demand returns post-pandemic, management has confidence commercial advances will continue.
Given the background – and recent positive news flow – here’s what every investor needs to know about OpGen. For a deeper dive, please read Edison’s latest research note.